GTBP Stock Overview
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
GT Biopharma, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$4.43 |
52 Week High | US$18.00 |
52 Week Low | US$3.52 |
Beta | 0.58 |
1 Month Change | 7.26% |
3 Month Change | -42.09% |
1 Year Change | -68.23% |
3 Year Change | -97.95% |
5 Year Change | -97.06% |
Change since IPO | -100.00% |
Recent News & Updates
Recent updates
We're Keeping An Eye On GT Biopharma's (NASDAQ:GTBP) Cash Burn Rate
Jan 06GT Biopharma files for $150M mixed shelf offering
Oct 13We Think GT Biopharma (NASDAQ:GTBP) Needs To Drive Business Growth Carefully
Sep 21GT Biopharma GAAP EPS of -$0.10 beats by $0.07
Aug 11Here's Why We're Watching GT Biopharma's (NASDAQ:GTBP) Cash Burn Situation
Jun 08Companies Like GT Biopharma (NASDAQ:GTBP) Are In A Position To Invest In Growth
Nov 24Getting To Know GT Biopharma
Jun 06GT Biopharma names Gregory Berk Chief Medical Officer
Apr 26Shareholder Returns
GTBP | US Biotechs | US Market | |
---|---|---|---|
7D | 16.3% | 0.9% | 0.2% |
1Y | -68.2% | 11.0% | 28.1% |
Return vs Industry: GTBP underperformed the US Biotechs industry which returned 10.3% over the past year.
Return vs Market: GTBP underperformed the US Market which returned 28.8% over the past year.
Price Volatility
GTBP volatility | |
---|---|
GTBP Average Weekly Movement | 13.3% |
Biotechs Industry Average Movement | 11.7% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GTBP's share price has been volatile over the past 3 months.
Volatility Over Time: GTBP's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1965 | 2 | Michael Breen | https://www.gtbiopharma.com |
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors.
GT Biopharma, Inc. Fundamentals Summary
GTBP fundamental statistics | |
---|---|
Market cap | US$6.03m |
Earnings (TTM) | -US$7.60m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs GTBP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GTBP income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$7.60m |
Earnings | -US$7.60m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -5.50 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did GTBP perform over the long term?
See historical performance and comparison